| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 145.16% | HC Wainwright & Co. | $33 → $19 | Maintains | Buy |
| 10/17/2023 | 325.81% | HC Wainwright & Co. | $30 → $33 | Maintains | Buy |
| 08/17/2023 | 287.1% | HC Wainwright & Co. | $32 → $30 | Maintains | Buy |
| 08/09/2023 | 325.81% | Oppenheimer | → $33 | Reiterates | Outperform → Outperform |
| 06/09/2023 | 312.9% | HC Wainwright & Co. | $46 → $32 | Maintains | Buy |
| 05/05/2023 | 209.68% | JMP Securities | $28 → $24 | Maintains | Market Outperform |
| 04/20/2023 | 61.29% | Jefferies | $16 → $12.5 | Upgrades | Underperform → Hold |
| 04/20/2023 | 338.71% | Stifel | $38 → $34 | Maintains | Buy |
| 04/19/2023 | 274.19% | JP Morgan | $42 → $29 | Maintains | Overweight |
| 04/19/2023 | 261.29% | JMP Securities | → $28 | Reiterates | → Market Outperform |
| 04/19/2023 | 274.19% | Raymond James | → $29 | Upgrades | Outperform → Strong Buy |
| 04/19/2023 | 93.55% | Barclays | $23 → $15 | Maintains | Equal-Weight |
| 04/18/2023 | 325.81% | Oppenheimer | → $33 | Maintains | Outperform |
| 04/13/2023 | 274.19% | Raymond James | → $29 | Initiates Coverage On | → Outperform |
| 04/05/2023 | 441.94% | JP Morgan | $45 → $42 | Maintains | Overweight |
| 03/07/2023 | 493.55% | HC Wainwright & Co. | $43 → $46 | Maintains | Buy |
| 02/03/2023 | 325.81% | Oppenheimer | → $33 | Initiates Coverage On | → Outperform |
| 01/19/2023 | 261.29% | JMP Securities | $38 → $28 | Maintains | Market Outperform |
| 11/07/2022 | 454.84% | HC Wainwright & Co. | $50 → $43 | Maintains | Buy |
| 09/30/2022 | 196.77% | Barclays | → $23 | Initiates Coverage On | → Equal-Weight |
| 09/14/2022 | 390.32% | JMP Securities | $35 → $38 | Maintains | Market Outperform |
| 09/12/2022 | 545.16% | HC Wainwright & Co. | $46 → $50 | Maintains | Buy |
| 09/02/2022 | 416.13% | Stifel | → $40 | Initiates Coverage On | → Buy |
| 08/09/2022 | 493.55% | HC Wainwright & Co. | $47 → $46 | Maintains | Buy |
| 06/06/2022 | 67.74% | Jefferies | → $13 | Initiates Coverage On | → Underperform |
| 05/24/2022 | 441.94% | Goldman Sachs | $49 → $42 | Maintains | Buy |
| 05/10/2022 | 506.45% | HC Wainwright & Co. | $54 → $47 | Maintains | Buy |
| 05/09/2022 | 351.61% | JMP Securities | $50 → $35 | Maintains | Market Outperform |
| 02/01/2022 | 480.65% | Berenberg | → $45 | Initiates Coverage On | → Buy |
| 08/17/2021 | 596.77% | HC Wainwright & Co. | $57 → $54 | Maintains | Buy |
| 07/21/2021 | 545.16% | B of A Securities | → $50 | Initiates Coverage On | → Buy |
| 01/29/2021 | 570.97% | JP Morgan | $36 → $52 | Maintains | Neutral |
| 12/15/2020 | 635.48% | HC Wainwright & Co. | $54 → $57 | Maintains | Buy |
| 12/08/2020 | 751.61% | JMP Securities | → $66 | Initiates Coverage On | → Market Outperform |
| 11/05/2020 | 596.77% | HC Wainwright & Co. | → $54 | Initiates Coverage On | → Buy |
What is the target price for Relay Therapeutics (RLAY)?
The latest price target for Relay Therapeutics (NASDAQ: RLAY) was reported by HC Wainwright & Co. on November 8, 2023. The analyst firm set a price target for $19.00 expecting RLAY to rise to within 12 months (a possible 145.16% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Relay Therapeutics (RLAY)?
The latest analyst rating for Relay Therapeutics (NASDAQ: RLAY) was provided by HC Wainwright & Co., and Relay Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Relay Therapeutics (RLAY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relay Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relay Therapeutics was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
Is the Analyst Rating Relay Therapeutics (RLAY) correct?
While ratings are subjective and will change, the latest Relay Therapeutics (RLAY) rating was a maintained with a price target of $33.00 to $19.00. The current price Relay Therapeutics (RLAY) is trading at is $7.75, which is out of the analyst's predicted range.